Related Experiment Video
Updated: Oct 6, 2026
07:28
Metabolic Profiling to Determine Bactericidal or Bacteriostatic Effects of New Natural Products using Isothermal Microcalorimetry
Published on: October 29, 2020
Treatment of respiratory tract infections with ciprofloxacin
The Journal of Antimicrobial Chemotherapy
|November 1, 1986
Abstract:
The efficacy and safety of ciprofloxacin in an oral dose of 750 mg twice daily, in the treatment of respiratory infections was studied in 129 patients. Ciprofloxacin showed broad in-vitro antibacterial activity and was highly effective in both Gram-negative and Gram-positive infections with a clinical cure rate of 96%. The major side effect was an interaction with theophylline particularly in the elderly patients.
Insights
Ciprofloxacin, an antibiotic, effectively treated respiratory infections in 96% of patients. Caution is advised due to potential theophylline interactions, especially in elderly individuals.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Medicine
Background:
- Respiratory infections pose a significant health burden.
- Broad-spectrum antibiotics are crucial for treating diverse bacterial pathogens.
- Ciprofloxacin is a fluoroquinolone antibiotic with known antibacterial properties.
Purpose of the Study:
- To evaluate the efficacy and safety of oral ciprofloxacin for respiratory infections.
- To assess the clinical cure rates associated with ciprofloxacin treatment.
- To identify potential adverse drug reactions and interactions.
Main Methods:
- A study involving 129 patients with respiratory infections.
- Oral administration of ciprofloxacin at 750 mg twice daily.
- In-vitro testing to determine antibacterial spectrum.
- Clinical monitoring for treatment outcomes and side effects.
Main Results:
- Ciprofloxacin demonstrated broad in-vitro activity against Gram-negative and Gram-positive bacteria.
- A high clinical cure rate of 96% was achieved.
- The primary adverse event noted was interaction with theophylline, particularly in elderly patients.
Conclusions:
- Oral ciprofloxacin is highly effective in treating respiratory infections.
- The drug exhibits a favorable safety profile, with theophylline interaction being the main concern.
- Further research may be warranted to explore management strategies for drug interactions in specific populations.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Acute Respiratory Failure-V
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:29Microbiota of the Respiratory Tract
The human respiratory tract, comprising the upper and lower segments, serves as a critical interface with the external environment. The upper respiratory tract (URT)—including the nostrils, sinuses, pharynx, and oropharynx—is heavily colonized by microbes, while the lower respiratory tract (LRT), composed of the larynx, trachea, bronchi, and lungs, was long thought to be sterile. However, recent molecular studies have revealed that the lungs are not devoid of microbes but act more like...
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...